利比韦林
医学
杜鲁特格拉维尔
养生
加药
人类免疫缺陷病毒(HIV)
重症监护医学
抗逆转录病毒疗法
药理学
外科
病毒载量
家庭医学
作者
Jean B. Nachega,Kimberly K. Scarsi,Monica Gandhi,Rachel K. Scott,Lynne Mofenson,Moherndran Archary,Sharon Nachman,Eric Decloedt,Elvin Geng,Lindsay Wilson,Angeli Rawat,John W. Mellors
出处
期刊:The Lancet HIV
[Elsevier]
日期:2023-04-14
卷期号:10 (5): e332-e342
被引量:32
标识
DOI:10.1016/s2352-3018(23)00051-6
摘要
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART.
科研通智能强力驱动
Strongly Powered by AbleSci AI